Is Vaccinex, Inc. overvalued or undervalued?

As of 8 November 2021, the valuation grade for Vaccinex, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative financial ratios, including a price-to-book value of -0.92 and an EV to EBITDA of -0.07, which suggest that the company is not generating positive returns or value for shareholders.
In comparison to its peers, Vaccinex's EV to EBIT ratio of -0.06 stands in stark contrast to Champions Oncology, Inc., which has a P/E ratio of 17.32, highlighting the disparity in financial health and market perception. Other peers, such as C4 Therapeutics, Inc., are also in a risky category with a P/E of -1.02, but they still reflect a better valuation outlook than Vaccinex. The company's significant underperformance is further illustrated by its one-year stock return of -87.21% compared to a 10.26% return for the S&P 500, reinforcing the notion that it is overvalued in its current state.